IL-6 Trans-Signaling Drives Murine Crescentic GN

Journal of the American Society of Nephrology

Volumn 27, Issue 1, 2016, Pages 132-142

  Braun, Gerald S ^a,b   Nagayama, Yoshikuni ^a,c   Maruta, Yuichi ^a,c   Heymann, Felix ^b   Van Roeyen, Claudia R ^a   Klinkhammer, Barbara M ^a,b   Boor, Peter ^a,b,d   Villa, Luigi ^a   Salant, David J ^e   Raffetseder, Ute ^a   Rose John, Stefan ^f   Ostendorf, Tammo ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^d Faculty of Natural Sciences   (Slovakia)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA; RESISTIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GLOMERULONEPHRITIS; MACROPHAGE; MALE; MESSENGER RNA SYNTHESIS; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN URINE LEVEL; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TH17 CELL; ANIMAL; BAGG ALBINO MOUSE; HUMAN; PHYSIOLOGY;

ANIMALS; GLOMERULONEPHRITIS; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; SIGNAL TRANSDUCTION;

EID: 84954436047     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111147     Document Type: Article

References (60)

1. Eitner F, Westerhuis R, Burg M, Weinhold B, Gröne HJ, Ostendorf T, Rüther U, Koch KM, Rees AJ, Floege J: Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 51: 69-78, 1997
2. Fukatsu A, Matsuo S, Tamai H, Sakamoto N, Matsuda T, Hirano T: Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest 65: 61-66, 1991
3. Malide D, Russo P, Bendayan M: Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 26: 558-564, 1995
4. Nagayama Y, Braun GS, Jakobs CM, Maruta Y, van Roeyen CR, Klinkhammer BM, Boor P, Villa L, Raffetseder U, Trautwein C, Görtz D, Müller-Newen G, Ostendorf T, Floege J: Gp130-dependent signaling in the podocyte. Am J Physiol Renal Physiol 307: F346-F355, 2014
5. Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, Maki S: Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 424: 459-464, 1994
6. Lee SJ, Borsting E, Declèves AE, Singh P, Cunard R: Podocytes express IL-6 and lipocalin 2/neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury. Nephron, ExpNephrol 121: E86-e96, 2012
7. Moriyama T, FujibayashiM, Fujiwara Y, Kaneko T, Xia C, Imai E, Kamada T, Ando A, Ueda N: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 6: 95-101, 1995
8. Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, LeJemtel TH, Bucciarelli L, KebschullM, Papapanou P, Uriel N, Schmidt AM, Sabbah HN, Jorde UP: Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. EurHeart J 35: 448-454, 2014
9. Karkar AM, Smith J, Tam FW, Pusey CD, Rees AJ: Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6. Kidney Int 52: 1313-1320, 1997
10. Luig M, Kluger MA, Goerke B, Meyer M, Nosko A, Yan I, Scheller J, Mittrucker HW, Rose-John S, Stahl RAK, Panzer U, Steinmetz OM: Inflammation induced IL-6 acts as a natural brake on macrophages and limits glomerulonephritis [published online ahead of print February 5, 2015]. J Am Soc Nephrol doi:10.1681/ASN2014060620
11. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ: Interleukin-6 exacerbates glomerulonephritis in (NZB 3 NZW)F1 mice. Am J Pathol 144: 927-937, 1994
12. Kiberd BA: Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 4: 58-61, 1993
13. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J: Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23: 85-97, 2012
14. Jones SA, Scheller J, Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121: 3375-3383, 2011
15. Huang XR, Tipping PG, Shuo L, Holdsworth SR: Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int 51: 94-103, 1997
16. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347: 911-920, 2002
17. Scholz J, Lukacs-Kornek V, Engel DR, Specht S, Kiss E, Eitner F, Floege J, Groene HJ, Kurts C: Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol 19: 527-537, 2008
18. Topham PS, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW: Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 104: 1549-1557, 1999
19. Murray PJ, Wynn TA: Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol 89: 557-563, 2011
20. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH: T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 307: 430-433, 2005
21. Lazarevic V,Glimcher LH, LordGM: T-bet: A bridge between innate and adaptive immunity. Nat Rev Immunol 13: 777-789, 2013
22. Tindemans I, Serafini N, Di Santo JP, Hendriks RW: GATA-3 function in innate and adaptive immunity. Immunity 41: 191-206, 2014
23. Hochheiser K, Engel DR, Hammerich L, Heymann F, Knolle PA, Panzer U, Kurts C: Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria. JAmSocNephrol 22: 306-316, 2011
24. Steinmetz OM, Summers SA, Gan PY, Semple T, Holdsworth SR, Kitching AR: The Th17-defining transcription factor RORgt promotes glomerulonephritis. J Am Soc Nephrol 22: 472-483, 2011
25. Cattell V:Nitric oxide andglomerulonephritis. Kidney Int 61: 816-821, 2002
26. Sun Q, Cheng D, Zhang M, He Q, Chen Z, Liu Z: Predominance of intraglomerular T-bet or GATA3may determinemechanismof transplant rejection. J Am Soc Nephrol 22: 246-252, 2011
27. Hoge J, Yan I, Jänner N, Schumacher V, Chalaris A, Steinmetz OM, Engel DR, Scheller J, Rose-John S, Mittrücker HW: IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 190: 703-711, 2013
28. Karbach S, Croxford AL, Oelze M, Schüler R, Minwegen D, Wegner J, Koukes L, YogevN,Nikolaev A, Reißig S,Ullmann A, KnorrM,Waldner M, Neurath MF, Li H, Wu Z, Brochhausen C, Scheller J, Rose-John S, Piotrowski C, Bechmann I, Radsak M, Wild P, Daiber A, von Stebut E, Wenzel P, Waisman A, Münzel T: Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasislike skin disease. Arterioscler Thromb Vasc Biol 34: 2658-2668, 2014
29. Scheller J,Garbers C, Rose-JohnS: Interleukin-6: Frombasicbiology toselective blockade of pro-inflammatory activities. Semin Immunol 26: 2-12, 2014
30. Jones SA, Fraser DJ, Fielding CA, Jones GW: Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant 30(4): 564-574, 2015
31. Yoshioka K, Takemura T, Murakami K, Okada M, Yagi K, Miyazato H, Matsushima K, Maki S: In situ expression of cytokines in IgA nephritis. Kidney Int 44: 825-833, 1993
32. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M, Katsuya T, Hoshida Y, Aozasa K, Ogihara T, Nishimoto N: Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 297: F679-F684, 2009
33. Hattori T, Fujitsuka N, Kurogi A, Shindo S: Effects of neutralizing antibodies on cytokine treatment for anti-GBMnephritis inmouse. Nippon Jinzo Gakkai Shi 38: 563-570, 1996
34. Suematsu S,Matsuda T, Aozasa K, Akira S,NakanoN,Ohno S,Miyazaki J, Yamamura K, Hirano T, Kishimoto T: IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 86: 7547-7551, 1989
35. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems RE, Blackburn MR, Xia Y: Interleukin 6 underlies angiotensin II-induced hypertension andchronic renal damage.Hypertension 59: 136-144, 2012
36. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, Axelrod JH: IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19: 1106-1115, 2008
37. Kuravi SJ, McGettrick HM, Satchell SC, Saleem MA, Harper L,Williams JM, Rainger GE, Savage CO: Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. J Immunol 193: 234-243, 2014
38. Le TT, Karmouty-Quintana H, Melicoff E, Le TT, Weng T, Chen NY, Pedroza M, Zhou Y, Davies J, Philip K, Molina J, Luo F, George AT, Garcia-Morales LJ, Bunge RR, Bruckner BA, Loebe M, Seethamraju H, Agarwal SK, Blackburn MR: Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol 193: 3755-3768, 2014
39. Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H: Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol 26: 80-87, 2014
40. Neurath MF, Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22: 83-89, 2011
41. WaldnerMJ, NeurathMF:Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 26: 75-79, 2014
42. Barkhausen T, Tschernig T, Rosenstiel P, vanGriensven M, Vonberg RP, Dorsch M, Mueller-Heine A, Chalaris A, Scheller J, Rose-John S, Seegert D, Krettek C, Waetzig GH: Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med 39: 1407-1413, 2011
43. Tsantikos E, Maxwell MJ, Putoczki T, Ernst M, Rose-John S, Tarlinton DM, HibbsML: Interleukin-6 trans-signalingexacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum 65: 2691-2702, 2013
44. Rovin BH, Parikh SV: Lupus nephritis: The evolving role of novel therapeutics. AmJ Kidney Dis 63: 677-690, 2014
45. Rovin BH, Van Vollenhoven R, Aranow C, Wagner C, Gordon R, Hsu B, Zhou B: Efficacy and safety of sirukumab in patients with active lupus nephritis: Results from a phase 2, multicenter, randomized, doubleblind, placebo-controlled, proof-of-concept study [Abstract]. J AmSoc Nephrol 25: 204A, 2014
46. Sumida K, Ubara Y, Suwabe T, Hayami N, Hiramatsu R, Hasegawa E, Yamanouchi M, Hoshino J, Sawa N, Takemoto F, Takaichi K, Ohashi K: Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford) 50: 1928-1930, 2011
47. Iijima T, Suwabe T, Sumida K, Hayami N, Hiramatsu R, Hasegawa E, YamanouchiM,Hoshino J, SawaN, TakaichiK,Oohashi K, Fujii T,Ubara Y: Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol 25: 138-142, 2015
48. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA,O'Donnell VB: Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 171: 315-325, 2007
49. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW: Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290: H935-H940, 2006
50. Zhou CC, Irani RA, Dai Y, Blackwell SC, Hicks MJ, Ramin SM, Kellems RE, Xia Y: Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol 186: 6024-6034, 2011
51. ClutterbuckR, Powles R,Millar J, Catovsky D: Interleukin-6 andothergp130-dependent cytokines selectively inhibitproliferationofmacrophage-lineage hemopoietic progenitor cells. Exp Hematol 28: 1120-1128, 2000
52. Riedy MC, Stewart CC: Inhibitory role of interleukin-6 in macrophage proliferation. J Leukoc Biol 52: 125-127, 1992
53. Fuster JJ, Walsh K: The good, the bad, and the ugly of interleukin-6 signaling. EMBO J 33: 1425-1427, 2014
54. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC: Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15: 423-430, 2014
55. Turner JE, Krebs C, Tittel AP, Paust HJ, Meyer-Schwesinger C, Bennstein SB, Steinmetz OM, Prinz I,Magnus T, Korn T, Stahl RA, Kurts C, Panzer U: IL-17A production by renal gd T cells promotes kidney injury in crescentic GN. J AmSoc Nephrol 23: 1486-1495, 2012
56. Sutton CE, Mielke LA, Mills KH: IL-17-producing gd T cells and innate lymphoid cells. Eur J Immunol 42: 2221-2231, 2012
57. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955-963, 2002
58. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grötzinger J, Rose-John S: I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15: 142-145, 1997
59. Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268: 160-167, 2001
60. Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, Hammerich L, Panzer U, Kaden S, Quaggin SE, Floege J, Gröne HJ, Kurts C: Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest 119: 1286-1297, 2009